查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591792

血液肿瘤检测市场：按产品和服务、癌症、技术、最终用户分类 - 全球预测 2025-2030

Hemato Oncology Testing Market by Products & Services (Assay Kits, Services), Cancer (Leukemia, Non-Hodgkin Lymphoma), Technology, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

血液肿瘤检测市场2023年估值为37.6亿美元，预计到2024年将达到43.6亿美元，复合年增长率为16.12%，到2030年将达到107.1亿美元。

血液肿瘤学检测包括对白血病、淋巴瘤和骨髓瘤等血癌的检测和管理至关重要的诊断和监测程序。血液肿瘤学检测的范围包括多种技术，例如基因检测、流式细胞技术、免疫化学和全血细胞计数检测。这些方法在个人化医疗中发挥重要作用，可以实现改善患者治疗效果的客製化治疗。血液肿瘤检测的需求源自于早期检测、准确的预后预测和有效的治疗监测的可能性。研究应用包括医院、门诊手术中心和诊断实验室，最终用途集中在医疗机构、研究机构和生物技术公司。推动市场成长的主要因素是血癌盛行率的增加、基于基因组的诊断的进步以及对个人化医疗的认识不断增强。次世代定序和液态切片等最新技术创新为提高诊断准确性和缩短週转时间提供了商机。然而，高昂的测试成本、有限的保险报销框架以及严格的监管要求等因素为市场拓展带来了重大挑战。为了克服这些障碍，公司需要专注于具有成本效益的解决方案，并瞄准医疗基础设施投资不断增加的新兴市场。研究和创新可能会在非侵入性检测技术、用于预测分析的人工智慧以及用于简化资料共用和患者管理的数位健康工具整合等领域蓬勃发展。市场竞争需要持续创新，研究机构、医疗保健提供者和科技公司之间的合作培育了一个能够带来突破性进展的生态系统。总体而言，血液肿瘤学检测前景广阔，但公司必须策略性地解决财务限制和监管障碍，并利用科学进步和跨部门伙伴关係来扩大业务成长并提高患者照护标准。

主要市场统计
基准年[2023] 37.6亿美元
预测年份 [2024] 43.6亿美元
预测年份 [2030] 107.1亿美元
复合年增长率（%） 16.12%

市场动态：快速发展的血液肿瘤检测市场的关键市场洞察

供需的动态交互作用正在改变血液肿瘤学检测市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 全球血癌盛行率不断上升
    • 消费者对个人化医疗的意识不断增强
    • 随着伙伴关係关係的扩大，新检测方法的快速开发
  • 市场限制因素
    • 缺乏标准的报销政策
  • 市场机会
    • 全球对先进治疗方案的需求不断增长
    • 不断研发推出新的测试方法
  • 市场挑战
    • 由于复杂的法律规范导致测试核准延迟

波特五力：驾驭血液肿瘤检测市场的策略工具

波特的「五力」框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解血液肿瘤检测市场的外部影响

外部宏观环境因素在塑造血液肿瘤检测市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解血液肿瘤检测市场的竞争状况

血液肿瘤测试市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的见解，使他们的公司能够应对日益激烈的竞争。

FPNV 定位矩阵血液肿瘤检测市场供应商的绩效评估

FPNV 定位矩阵是评估血液肿瘤检测市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了血液肿瘤检测市场的成功之路

血液肿瘤检测市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球血癌发生率上升
      • 消费者对个人化医疗越来越了解
      • 扩大伙伴关係以快速开发新的检测方法
    • 抑制因素
      • 缺乏标准退费政策
    • 机会
      • 全球对先进治疗方法的需求不断增长
      • 持续研究和开发引入新的测试程序
    • 任务
      • 复杂的法规结构延迟了测试核准
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章血液肿瘤检测市场（依产品及服务）

  • 检测试剂套件
  • 服务

第七章血液肿瘤检测市场癌症

  • 白血病
  • 非何杰金氏淋巴瘤

第八章血液肿瘤检测市场：依技术分类

  • 国际卫生
  • 下一代种子
  • PCR

第九章血液肿瘤测试市场：依最终用户分类

  • 临床实验室
  • 医院

第十章北美和南美血液肿瘤检测市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区血液肿瘤检测市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲血液肿瘤检测市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Bio-Rad Laboratories, Inc.
  • Boule Diagnostics AB
  • Danaher Corporation
  • Diatron Medical Instruments Limited
  • EKF Diagnostics Holdings PLC
  • F. Hoffmann-La Roche Ltd.
  • HORIBA, Ltd.
  • Icon PLC
  • Illumina, Inc.
  • Mindray Bio-Medical Electronics Co., Ltd.
  • Nihon Kohden Corporation
  • Sanofi SA
Product Code: MRR-437E9896A58A

The Hemato Oncology Testing Market was valued at USD 3.76 billion in 2023, expected to reach USD 4.36 billion in 2024, and is projected to grow at a CAGR of 16.12%, to USD 10.71 billion by 2030.

Hemato oncology testing involves diagnostic and monitoring procedures essential for detecting and managing blood cancers such as leukemia, lymphoma, and myeloma. The scope of hemato oncology testing encompasses various techniques, including genetic testing, flow cytometry, immunochemistry, and complete blood count tests. These methods play a crucial role in personalized medicine, enabling tailored treatments that improve patient outcomes. The necessity for hemato oncology testing arises from its potential to offer early detection, precise prognosis, and effective treatment monitoring. Applications extend to hospitals, ambulatory surgical centers, and diagnostic laboratories, with end-use scope centered around healthcare institutions, research academies, and biotech firms. Market growth is primarily driven by an increasing prevalence of blood cancers, advancements in genome-based diagnostics, and heightened awareness of personalized medicine. Recent technological innovations, such as next-generation sequencing and liquid biopsy, offer lucrative opportunities for businesses to enhance diagnostic accuracy and reduce turnaround times. However, factors such as high testing costs, limited reimbursement frameworks, and stringent regulatory requirements pose significant challenges to market expansion. To overcome these obstacles, companies need to focus on cost-effective solutions and target emerging markets where investment in healthcare infrastructure is rising. Research and innovation can thrive in areas like non-invasive testing technologies, artificial intelligence for predictive analytics, and integration of digital health tools for streamlined data sharing and patient management. The competitive nature of the market requires continuous innovation, with collaboration among research entities, healthcare providers, and technology firms fostering an ecosystem conducive to groundbreaking advancements. Overall, hemato oncology testing holds promising prospects, but businesses must strategically address financial constraints and regulatory hurdles, leveraging scientific advancements and cross-sector partnerships to drive business growth and enhance patient care standards.

KEY MARKET STATISTICS
Base Year [2023] USD 3.76 billion
Estimated Year [2024] USD 4.36 billion
Forecast Year [2030] USD 10.71 billion
CAGR (%) 16.12%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hemato Oncology Testing Market

The Hemato Oncology Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of hematologic cancer globally
    • Rising awareness on personalized medicine among consumers
    • Rapid development of new assays with growing partnerships
  • Market Restraints
    • Lack of standard reimbursement policies
  • Market Opportunities
    • Emerging demand for advanced treatment options globally
    • Ongoing research and development for the introduction of new testing procedures
  • Market Challenges
    • Complicated regulatory framework results in delayed approval of tests

Porter's Five Forces: A Strategic Tool for Navigating the Hemato Oncology Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hemato Oncology Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hemato Oncology Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hemato Oncology Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hemato Oncology Testing Market

A detailed market share analysis in the Hemato Oncology Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hemato Oncology Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hemato Oncology Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hemato Oncology Testing Market

A strategic analysis of the Hemato Oncology Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hemato Oncology Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Boule Diagnostics AB, Danaher Corporation, Diatron Medical Instruments Limited, EKF Diagnostics Holdings PLC, F. Hoffmann-La Roche Ltd., HORIBA, Ltd., Icon PLC, Illumina, Inc., Mindray Bio-Medical Electronics Co., Ltd., Nihon Kohden Corporation, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Hemato Oncology Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Products & Services, market is studied across Assay Kits and Services.
  • Based on Cancer, market is studied across Leukemia and Non-Hodgkin Lymphoma.
  • Based on Technology, market is studied across IHC, NGS, and PCR.
  • Based on End-User, market is studied across Clinical Laboratories and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of hematologic cancer globally
      • 5.1.1.2. Rising awareness on personalized medicine among consumers
      • 5.1.1.3. Rapid development of new assays with growing partnerships
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of standard reimbursement policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging demand for advanced treatment options globally
      • 5.1.3.2. Ongoing research and development for the introduction of new testing procedures
    • 5.1.4. Challenges
      • 5.1.4.1. Complicated regulatory framework results in delayed approval of tests
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hemato Oncology Testing Market, by Products & Services

  • 6.1. Introduction
  • 6.2. Assay Kits
  • 6.3. Services

7. Hemato Oncology Testing Market, by Cancer

  • 7.1. Introduction
  • 7.2. Leukemia
  • 7.3. Non-Hodgkin Lymphoma

8. Hemato Oncology Testing Market, by Technology

  • 8.1. Introduction
  • 8.2. IHC
  • 8.3. NGS
  • 8.4. PCR

9. Hemato Oncology Testing Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinical Laboratories
  • 9.3. Hospitals

10. Americas Hemato Oncology Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hemato Oncology Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hemato Oncology Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Adaptive Biotechnologies Corporation
  • 3. Bio-Rad Laboratories, Inc.
  • 4. Boule Diagnostics AB
  • 5. Danaher Corporation
  • 6. Diatron Medical Instruments Limited
  • 7. EKF Diagnostics Holdings PLC
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. HORIBA, Ltd.
  • 10. Icon PLC
  • 11. Illumina, Inc.
  • 12. Mindray Bio-Medical Electronics Co., Ltd.
  • 13. Nihon Kohden Corporation
  • 14. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. HEMATO ONCOLOGY TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. HEMATO ONCOLOGY TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEMATO ONCOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEMATO ONCOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMATO ONCOLOGY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMATO ONCOLOGY TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY IHC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY NGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMATO ONCOLOGY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY PRODUCTS & SERVICES, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM HEMATO ONCOLOGY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. HEMATO ONCOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 189. HEMATO ONCOLOGY TESTING MARKET, FPNV POSITIONING MATRIX, 2023